This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): darexaban maleate
Description: YM150 is an oral Factor Xa inhibitor. Factor Xa is an enzyme that leads to blood clot formation by converting prothrombin to thrombin. The antithrombotic agent is being developed for two applications, prevention of venous thromboembolism (VTE) after orthopedic surgery and prevention of thromboembolism accompanying atrial fibrillation (AF).
Deal Structure: In April 2005, Yamanouchi and Fujisawa merged to form Astellas Pharma.
Additional information available to subscribers only: